László Szekeres

16. Szekeres L., Pharmacological induction of delayed and prolonged cardiac protection: The role of prostanoids. Experimental & Clinical Cardiol. 9: 7–12, 2004. Note: Drug or physical loading induced late appearing protection of the heart from severe stress by adaptation to stress

1. Szekeres L. [A szívglycosidoktól a gyógyszeres stressadaptációig. Egy ötvenéves kutatómunka tanulságai.] In: Juhász-Nagy S, editor. Studia Physiologica 7. Budapest: Scientia Kiadó; 2000. p. 1–95.

15. Szekeres L. Delayed adaptation to stress. A clinically useful form of cardiac protection. Exp Clin Cardiol 2000; 5: 116–121. (Note: Drug or physical loading induced late appearing protection of the heart from severe stress by adaptation to stress)

18. Szekeres L, Szilvássy Z, Ferdinandy P, et al. Delayed cardiac protection against harmful consequences of stress can be induced in experimental atherosclerosis in rabbits. J Mol Cell Cardiol 1997; 29: 1977–1983.

14. Szekeres L. On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Can J Cardiol 1996;12: 177–185. Note: Drug or physical loading induced late appearing protection of the heart from severe stress by adaptation to stress

19. L. Szekeres (1995) Drug induced delayed cardiac protection against the effects of myocardial ischemia Pharmacology and Therapeutics, 108: 269-280

17. Udvary E, Vegh A, Szekeres L. 7-oxo-PGI2 induced late protective action from arrhythmias due to local myocardial ischemia. Bratisl Lek Listy 1991; 92: 146–149. Note: Demonstration of unlimited prolongation of cardiac protection from severe stress by adaptation to stress

He married Lenke Rudas MD, former associate professor in the Department of Dentistry of the University of Pécs and later of the University of Szeged (Died 1990). They had two daughters: Julia Barthó-Szekeres MD. PhD. DSc., Professor and Head of the Department of Microbiology at the University of Pécs (born 1950) and Zsuzsa Szekeres MD, pediatrician in Budapest (born 1954). In 1993 he married Ibolya Pamuk.

11. Szekeres L, Udvary E, Vegh A. Nifedipine effects in severe myocardial ischaemia in the dog due to left anterior descending coronary occlusion with left circumflex coronary artery constriction. Br J Pharmacol 1987; 91: 127–37. (Note: Important methodological innovation)

12. Csete K, Kovacs GL, Szekeres L. Disturbance of motoric function as behavioral measure of impaired cerebral circulation in mice. Physiol Behav 1986; 36: 409–412. (Note: Important methodological innovation)

13. Szekeres L. Sudden Death due to Acute Myocardial Infarction. (A monograph) Boca Raton, Florida: CRC Press Inc.; 1986. p. 1- 288.

9. Lepran I, Koltai M, Siegmund W, Szekeres L. Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats. J Pharmacol Methods 1983; 9: 219–230. (Note: Important methodological innovation)

10. Lepran I, Nemecz G, Koltai M, Szekeres L. Effect of a linoleic acid-rich diet on the acute phase of coronary occlusion in conscious rats: influence of indomethacin and aspirin. J Cardiovasc Pharmacol 1981; 3: 847–853. (Note: worldwide the first exact experimental demonstration of the protection from lethal arrhythmias due to coronary occlusion of a diet rich in unsaturated fatty acids)

8. Szekeres L, Csik V, Udvary E. Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. J Pharmacol Exp Ther 1976; 196: 15–28. (Note: Important methodological innovation)

7. Szekeres L, Szurgent J. A new type of electrode for continuous recording of monophasic action potentials from the heart in situ. Cardiovasc Res 1974; 8:132–137.(Note: Important methodological innovation)

4. Szekeres L, Papp JG. Experimental Cardiac Arrhythmias and Antiarrhythmic Drugs. (Monograph) Budapest: Akadémiai Kiadó; 1971. p. 1-448.

6. Szekeres L, Vaughan Williams EM. Antifibrillatory action. J Physiol (London) 1962; 160: 470–482.

3. Szekeres L, Méhes J, Papp J Gy. Mechanism of increased susceptibility to fibrillation of the hypothermic mammalian heart in situ. Br J Pharmacol 1961; 17: 167–175.

5. Vaughan Williams EM, Szekeres L. A comparison of tests for antifibrillatory action. Br J Pharmacol 1961; 17: 424–432.

2. Szekeres L, Schein M. Cell metabolism of the overloaded mammalian heart in situ. Kardiologia (Basel) 1959; 34: 19–27.

He graduated from high school in Győr and in 1949 he graduated at the Medical School of the University of Pécs. He worked as intern in the Institute of Pharmacology at the same university. His original plan was to become a clinical physician, but after graduation he decided to stay in the Institute of Pharmacology. In 1959 and 1960 he did a few months postgraduate work in Moscow and Leningrad (now St. Petersburg) in the Pharmacological Institutes of the USSR Academy of Medical Sciences. In 1960-61 he completed a Riker fellowship at the Department of Pharmacology of the University of Oxford. In 1963 he spent two months in the "Istituto Superiore di Sanitá" in Rome to study methods concerning cerebral circulation with the Nobel-prize laureate Professor Bovet. In 1982 he studied at the National Institute of Health and at the Food and Drug Administration in Washington, DC.

Since 1948 he regularly participated and gave lectures in Hungary and abroad at national and international congresses and symposia including most European countries, USA, Canada, Australia, Israel, Japan, India and China.

He had 295 articles in scientific journals, wrote 76 book chapters, 304 abstracts and 7 edited books. Although publications of L. Szekeres started from 1948, the number of citations (2260) and the impact factor (238.25) are taken into account only for the period of 1961-2005. The following is a list of his most important works.

László Szekeres (July 4, 1921 in Győr, Hungary – January 9, 2012 in Szeged, Hungary). Professor Emeritus, Institute of Pharmacology and Therapeutics, Medical Faculty of the University of Szeged, Hungary. He has held a number of notable positions and received a number of awards. His research contributed to the development of cardiac drugs.